Cihlar T - Search Results

1

Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.

Boojamra CG, Parrish JP, Sperandio D, Gao Y, Petrakovsky OV, Lee SK, Markevitch DY, Vela JE, Laflamme G, Chen JM, Ray AS, Barron AC, Sparacino ML, Desai MC, Kim CU, Cihlar T, Mackman RL. Boojamra CG, et al. Among authors: cihlar t. Bioorg Med Chem. 2009 Feb 15;17(4):1739-46. doi: 10.1016/j.bmc.2008.12.028. Epub 2008 Dec 24. Bioorg Med Chem. 2009. PMID: 19179082

2

Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

Miller MD, Lamy PD, Fuller MD, Mulato AS, Margot NA, Cihlar T, Cherrington JM. Miller MD, et al. Among authors: cihlar t. Mol Pharmacol. 1998 Aug;54(2):291-7. doi: 10.1124/mol.54.2.291. Mol Pharmacol. 1998. PMID: 9687570

3

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

Birkus G, Hitchcock MJ, Cihlar T. Birkus G, et al. Among authors: cihlar t. Antimicrob Agents Chemother. 2002 Mar;46(3):716-23. doi: 10.1128/AAC.46.3.716-723.2002. Antimicrob Agents Chemother. 2002. PMID: 11850253 Free PMC article.

4

Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Cihlar T, et al. Antiviral Res. 2002 Apr;54(1):37-45. doi: 10.1016/s0166-3542(01)00210-8. Antiviral Res. 2002. PMID: 11888656

5

Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells.

Birkus G, Gibbs CS, Cihlar T. Birkus G, et al. Among authors: cihlar t. J Viral Hepat. 2003 Jan;10(1):50-4. doi: 10.1046/j.1365-2893.2003.00399.x. J Viral Hepat. 2003. PMID: 12558912

6

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.

Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. Lee WA, et al. Among authors: cihlar t. Antimicrob Agents Chemother. 2005 May;49(5):1898-906. doi: 10.1128/AAC.49.5.1898-1906.2005. Antimicrob Agents Chemother. 2005. PMID: 15855512 Free PMC article.

7

Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.

Cihlar T, He GX, Liu X, Chen JM, Hatada M, Swaminathan S, McDermott MJ, Yang ZY, Mulato AS, Chen X, Leavitt SA, Stray KM, Lee WA. Cihlar T, et al. J Mol Biol. 2006 Oct 27;363(3):635-47. doi: 10.1016/j.jmb.2006.07.073. Epub 2006 Aug 2. J Mol Biol. 2006. PMID: 16979654

8

Mechanism of active renal tubular efflux of tenofovir.

Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR. Ray AS, et al. Among authors: cihlar t. Antimicrob Agents Chemother. 2006 Oct;50(10):3297-304. doi: 10.1128/AAC.00251-06. Antimicrob Agents Chemother. 2006. PMID: 17005808 Free PMC article.

9

Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.

Ray AS, Cihlar T. Ray AS, et al. Among authors: cihlar t. J Infect Dis. 2007 May 1;195(9):1389-90; author reply 1390-1. doi: 10.1086/513282. J Infect Dis. 2007. PMID: 17397012 No abstract available.

10

Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, Roy A, Rhodes GR. Cihlar T, et al. Antivir Ther. 2007;12(2):267-72. Antivir Ther. 2007. PMID: 17503669

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

150 results

Search Page